Pharmaceuticals News and Research

RSS

Valeant subsidiary to acquire leading skin care brands in Australia

Valeant Pharmaceuticals International, Inc. announced today that its subsidiary, Biovail Laboratories International SRL (BLS), has agreed to acquire several privately–owned pharmacy skin care brands in Australia. The leading brands, including well-established local brands such as Hamilton's Suncare and Hamilton's Skin Therapy, are ranked #2 in suncare in the Australian pharmacy market.

29 Oct 2010

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

Cipher Pharmaceuticals Inc. today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug Administration (FDA).

29 Oct 2010

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals, Inc. today announced new data from the FREEDOM-301 Phase 3 trial of its investigational LEVADEX orally inhaled migraine therapy showing low recurrence rates with LEVADEX. Eight additional analyses from the LEVADEX program also will be presented during the 2010 European Headache and Migraine Trust International Congress (EHMTIC) in Nice, France.

29 Oct 2010

Merck reports $342 million net income for 2010 third quarter

Merck & Co., Inc. today announced financial results for the third quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the third quarter of $0.85, which excludes purchase accounting adjustments, restructuring costs, merger-related expenses and a $950 million legal reserve.

29 Oct 2010

BioClinica enters five-year enterprise-wide agreement for Optimizer technology

BioClinica, Inc., a global provider of clinical trial management services, today announced that a Top Ten pharmaceutical company has entered into a five-year enterprise-wide agreement for BioClinica Optimizer to simulate and forecast clinical trial supply scenarios for their worldwide clinical trial operations.

From Clario 29 Oct 2010

New solvent system could provide ways of producing nanometer-scale cancer chemotherapy agents

Noble metals such as platinum and palladium are becoming increasingly important because of growth in environmentally friendly applications such as fuel cells and pollution control catalysts. But the world has limited quantities of these materials, meaning manufacturers will have to rely on efficient recycling processes to help meet the demand.

29 Oct 2010

Aceto named on 'ICIS Top 100 Chemical Distributors' list

Aceto Corporation, a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of pharmaceuticals, nutraceuticals, specialty chemicals and crop protection products, today announced that they were selected as one of the "ICIS Top 100 Chemical Distributors", a listing of the world's leading companies serving buyers of chemicals based on calendar 2009 sales.

29 Oct 2010

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Shire plc the global specialty biopharmaceutical company, today announced results from a Phase 2 signal finding study of Vyvanse(R) [lisdexamfetamine dimesylate (or SPD489)] in patients who have had residual symptoms of depression following treatment with LEXAPRO(escitlopram) for Major Depressive Disorder (MDD).

29 Oct 2010

Magellan reports $750.3 million net revenue for third quarter 2010

Magellan Health Services, Inc. today reported financial results for the third quarter of 2010, as summarized below, and increased guidance for the full year. For the quarter ended September 30, 2010, the Company reported net revenue of $750.3 million, segment profit of $90.1 million, and net income of $44.8 million or $1.31 per diluted common share.

29 Oct 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

Shire plc the global specialty biopharmaceutical company, today presented research results of once-daily INTUNIV (guanfacine) Extended-Release Tablets, coadministered with stimulants in children and adolescents diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who had suboptimal response to treatment with a long-acting stimulant alone.

29 Oct 2010

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

After receiving a priority review, Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved SPRYCEL (dasatinib) 100 mg once daily for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase.

29 Oct 2010

Maxygen sells MolecularBreeding platform technology to Codexis for $20M

Maxygen, Inc., a biotechnology company focused on the development of improved protein drugs, today announced that it has sold its MolecularBreeding™ platform technology to Codexis, Inc. for $20 million in cash.

29 Oct 2010

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

DiaGenic: The interim report for the third quarter 2010 was approved by the Board of Directors on 28 October 2010.

29 Oct 2010

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

ACADIA Pharmaceuticals Inc. today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., pursuant to which ACADIA and BLS have agreed to conclude their previously established collaboration to develop and commercialize pimavanserin in the United States and Canada.

29 Oct 2010

Baxter to divest U.S. generic injectables business to Hikma

Baxter International Inc. announced today that it has entered into a definitive agreement to divest its U.S. generic injectables business to Hikma Pharmaceuticals PLC. The consideration for the divestiture arrangement totals approximately $112 million, subject to closing adjustments.

From Baxter International Inc. 29 Oct 2010

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Researchers have identified two small-molecule inhibitors that effectively targeted the focal adhesion kinase (FAK), an enzyme present in certain cancers that helps tumors thrive and survive.

29 Oct 2010

Regulus receives $10M equity investment from sanofi-aventis

Regulus Therapeutics Inc. announced today that the Company has received a $10 million equity investment from sanofi-aventis in connection with the landmark alliance the two companies entered into on June 21, 2010. The equity investment by sanofi-aventis further strengthens the balance sheet of Regulus, and with this investment sanofi-aventis becomes the third investor in Regulus, along with its founding companies Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc..

29 Oct 2010

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

The U.S. Food and Drug Administration today approved a new indication for Sprycel (dasatinib) for the treatment of a rare blood cancer when it is first diagnosed. The cancer, called Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML), is a slowly progressing blood and bone marrow disease linked to a genetic abnormality.

29 Oct 2010

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

The first national outcome-based contract between a pharmaceutical company and a pharmacy benefit management company resulted in an increase in the number of people with type 2 diabetes who were able to control their blood sugar levels by taking their medications appropriately.

29 Oct 2010

Sanofi-aventis to acquire BMP Sunstone

Sanofi-aventis and BMP Sunstone Corporation announced today that they have entered into a definitive agreement under which sanofi-aventis is to acquire all outstanding shares of BMP Sunstone for cash consideration of USD 10 per share, or a total of approximately USD 520.6 million on a fully diluted basis.

29 Oct 2010

Pharmaceuticals News and Research

Valeant subsidiary to acquire leading skin care brands in Australia

Cipher completes enrolment in CIP-ISOTRETINOIN Phase III study for severe, nodular acne

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

Merck reports $342 million net income for 2010 third quarter

BioClinica enters five-year enterprise-wide agreement for Optimizer technology

New solvent system could provide ways of producing nanometer-scale cancer chemotherapy agents

Aceto named on 'ICIS Top 100 Chemical Distributors' list

Shire announces results of Vyvanse Phase 2 signal finding study for Major Depressive Disorder

Magellan reports $750.3 million net revenue for third quarter 2010

Coadministration of INTUNIV tablets with stimulant reduces ADHD symptoms

SPRYCEL receives FDA approval for treating adult patients with Ph+ CML in chronic phase

Maxygen sells MolecularBreeding platform technology to Codexis for $20M

DiaGenic third quarter income increases from NOK -9.3 million to NOK -9.6 million

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

Baxter to divest U.S. generic injectables business to Hikma

Researchers identify small-molecule inhibitors that effectively target FAK enzyme in colon cancer

Regulus receives $10M equity investment from sanofi-aventis

FDA approves Sprycel for treatment of adults with Ph+ CP-CML

Outcome-based contract between CIGNA and Merck helps diabetics control blood sugar levels

Sanofi-aventis to acquire BMP Sunstone

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence